A groundbreaking drug has gained approval from the US Food and Drug Administration (FDA) for addressing metastatic pancreatic cancer. This innovative medication, Rasonque (daraxonrasib), obstructs Ras proteins, which are associated with numerous cancer types and were previously deemed ‘undruggable’. Pancreatic cancer is a harsh illness, with a mere five-year survival rate of 8% for patients […]
Read More